Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics;
for example, it is recommended that agents with a short plasma half-life be administered
multiple times per day. However, to date, several randomized controlled trials (RCTs) have
shown no differences in clinical outcomes between once- and twice-daily dosing of various
antipsychotics, suggesting that once-daily dosing of antipsychotics is a viable option
regardless of plasma half-life. This would apply to clozapine as well; however, there have
been no studies comparing once-daily vs. twice-daily dosing regimens of clozapine in terms of
efficacy and tolerability. To address this gap in the literature, the investigators shall
conduct a pilot, double-blind, RCT to examine efficacy and tolerability following a switch to
once-daily dosing regimen of clozapine in patients with schizophrenia receiving clozapine
twice a day.